Consolidated Statements Of Cash Flow - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash Flows From Operating Activities:
Net (Loss)	$ (6,529,521)	$ (4,742,023)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	129,076	130,215
Share Based Compensation - Non-employee	68,654	19,071
Share Based Compensation- Employees	1,107,349	2,259,316
Increase in Inventory Reserves	1,296,954
Loss on Disposal of Assets	3,083	3,350
Loss (gain) on Sale of Investments Available for Sale	2,892
Changes in Assets and Liabilities:
(Increase) Decrease in Accounts Receivable	295,973	(344,500)
(Increase) in Inventory	59,427	(2,291,108)
(Increase) in Other Assets	238,438	160,406
Increase (Decrease) in Accounts Payable	(209,208)	(1,914,780)
Increase (Decrease) in Other Liabilities	(494,969)	2,160,268
Increase (decrease) Deferred License Revenue	(504,528)	(498,120)
Increase (decrease) in deferred drug license revenue	(68,181)	(93,181)
Changes in Assets and Liabilities	(683,048)	(2,821,015)
Cash (Used In) Operating Activities	(4,604,561)	(5,151,086)
Cash Flows From Investing Activities:
Purchase of Investments Available for Sale	(1,416,665)
Sale of Investments Available for Sale	1,050,554	31,123
Purchase of Equipment	(155,712)	(162,003)
Proceeds on Sale of Assets		450
Cash Provided by Investing Activities	(521,823)	(130,430)
Cash Flows From Financing Activities:
Effects of exchange rate changes	(2,446)	632
(Decrease) In Cash	(5,128,830)	(5,280,884)
Cash At Beginning Of Period	8,406,917	17,180,594
Cash At End Of Period	$ 3,278,087	$ 11,899,710